Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Sep;2(3):559-71.
doi: 10.1007/s11302-006-9012-4. Epub 2006 Jul 8.

Characterization of human and rodent native and recombinant adenosine A(2B) receptors by radioligand binding studies

Affiliations

Characterization of human and rodent native and recombinant adenosine A(2B) receptors by radioligand binding studies

Daniela C G Bertarelli et al. Purinergic Signal. 2006 Sep.

Abstract

Adenosine A(2B) receptors of native human and rodent cell lines were investigated using [(3)H]PSB-298 [(8-{4-[2-(2-hydroxyethylamino)-2-oxoethoxy]phenyl}-1-propylxanthine] in radioligand binding studies. [(3)H]PSB-298 showed saturable and reversible binding. It exhibited a K(D) value of 60 +/- 1 nM and limited capacity (B(max) = 3.511 fmol per milligram protein) at recombinant human adenosine A(2B) receptors expressed in human embryonic kidney cells (HEK-293). The addition of sodium chloride (100 mM) led to a threefold increase in the number of binding sites recognized by the radioligand. The curve of the agonist 5'-N-ethylcarboxamidoadenosine (NECA) was shifted to the right in the presence of NaCl, while the curve of the antagonist PSB-298 was shifted to the left, indicating that PSB-298 may be an inverse agonist at A(2B) receptors. Adenosine A(2B) receptors were shown to be the major adenosine A(2) receptor subtype on the mouse neuroblastoma x rat glioma hybrid cell line NG108-15 cells. Binding studies at rat INS-1 cells (insulin secreting cell line) demonstrated that [(3)H]PSB-298 is a selective radioligand for adenosine A(2B) binding sites in this cell line.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of antagonist radioligands used for adenosine A2B receptor binding assays
Figure 2
Figure 2
Preparation of [3H]PSB-298 from the propargyl precursor PSB-297 by catalytic hydrogenation (* denotes position of radiolabel)
Figure 3
Figure 3
Electropherogram of [3H]PSB-298 in the presence of PSB-297 as an internal standard. The separation conditions were 150 mM Tris-HCl, 100 mM sodium dodecyl sulfate, pH 9.1, fused silica capillary, 37 cm length (30 cm to the detector), 75 µM I.D.; 10 kV; 25°C; detection at 321 nm; pressure injection (0.5 p.s.i., 5 s)
Figure 4
Figure 4
UV spectrum of PSB-298 (at a concentration of 0.01 mg/ml)
Figure 5
Figure 5
Kinetics of [3H]PSB-298 binding (1 nM) to membranes recombinantly expressing the human adenosine A2B receptor at 25°C. A Association curve, B dissociation curve. Dissociation was initiated by the addition of 1 mM NECA (final concentration) after 180 min of pre-incubation. Experiments revealed a kinetic KD value of 25 nM. Data points represent means from a typical experiment performed in duplicates
Figure 6
Figure 6
Saturation experiment of [3H]PSB-298 binding to human adenosine A2B receptors recombinantly expressed in HEK-293 cells. The Scatchard-Rosenthal plot of the saturation binding experiment visualizes the presence of one single class of binding sites. Total binding (▪), specific binding (•), nonspecific binding (≆)
Figure 7
Figure 7
Effects of different concentrations of sodium chloride on radioligand binding to recombinant human adenosine A2B receptors expressed in HEK-293 cell membranes. Membranes (50 µg) were incubated for 60 min at 25°C with 1 nM [3H]PSB-298. Non-specific binding was determined with 1 mM NECA. The data are means of four independent experiments ± SEM
Figure 8
Figure 8
Effect of sodium chloride (100 mM) on the binding of the antagonist PSB-298 and the agonist NECA, respectively, versus the radioligand [3H]PSB-298. Sodium shift experiments were performed at human A2B adenosine receptors expressed in HEK-293 cell membranes with 1 nM [3H]PSB-298 and 50 µg of protein
Figure 9
Figure 9
Competition experiments of the antagonists caffeine, theophylline, alloxazine and CGS-15943 (a) and the agonists CADO, CPA and NECA (b) versus 1 nM [3H]PSB-298 performed at human recombinant adenosine A2B receptors expressed in HEK-293 cells
Figure 10
Figure 10
Saturation of [3H]PSB-298 binding to native adenosine A2B receptors in NG108-15 cells. The curve is representative of a single experiment from four independent experiments performed in duplicate
Figure 11
Figure 11
Inhibition of [3H]PSB-298 binding to INS-1 cells by CHA, CGS-21680 and Cl-IB-MECA. INS-1 cells were incubated for 80 min at 22°C in 200 µl KRH buffer containing 5.6 mM glucose, 20 nM [3H] PSB-298, and increasing concentrations of indicated compounds. Results are expressed as percent of maximum specifically bound radioactivity (non-specific binding in the presence of 1 mM unlabeled NECA was subtracted). Each value represents the mean ± SEM of five separate experiments
Figure 12
Figure 12
Inhibition of [3H]PSB-298 binding to INS-1 cells by PSB- 53 and PSB-1115. INS-1 cells were incubated for 80 min at 22°C in 200 µl KRH buffer containing 5.6 mM glucose, 20 nM [3H] PSB-298, 1 mM CHA (adenosine A1 receptor agonist) and increasing concentrations of indicated compounds (adenosine A2B receptor antagonists). Results are expressed as percent of maximum specifically bound radioactivity (non-specific binding in the presence of 1 mM unlabeled NECA was subtracted). Each value represents the mean ± SEM of five separate experiments

Similar articles

Cited by

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2174/1568026033392264', 'is_inner': False, 'url': 'https://doi.org/10.2174/1568026033392264'}, {'type': 'PubMed', 'value': '12570760', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12570760/'}]}
    2. Volpini R, Costanzi S, Vittori S et al (2003) Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem 3:427–33 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1038/sj.bjp.0706272', 'is_inner': False, 'url': 'https://doi.org/10.1038/sj.bjp.0706272'}, {'type': 'PMC', 'value': 'PMC1576223', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1576223/'}, {'type': 'PubMed', 'value': '15980878', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15980878/'}]}
    2. Holgate ST (2005) The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol 145:1009–015 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1124/jpet.103.056036', 'is_inner': False, 'url': 'https://doi.org/10.1124/jpet.103.056036'}, {'type': 'PubMed', 'value': '14563788', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14563788/'}]}
    2. Abo-Salem OM, Hayallah AM, Bilkei-Gorzo A et al (2004) Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther 308:358–66 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0165-6147(98)01179-1', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0165-6147(98)01179-1'}, {'type': 'PubMed', 'value': '9612090', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9612090/'}]}
    2. Feoktistov I, Polosa R, Holgate ST et al (1998) Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci 19:148–53 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1021/jm990499b', 'is_inner': False, 'url': 'https://doi.org/10.1021/jm990499b'}, {'type': 'PubMed', 'value': '11170626', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11170626/'}]}
    2. Harada H, Asano O, Hoshino Y et al (2001) 2-Alkynyl-8-aryl-9-methyladenosines as novel adenosine receptor antagonists: their synthesis and structure–activity relationship toward hepatic glucose production induced via agonism of the A2B receptor. J Med Chem 44:170–79 - PubMed

LinkOut - more resources